BioRestorative Therapies (BRTX) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 12, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		10,453,936
Trading Symbol	BRTX
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash	$ 105,374	$ 451,680
Accounts receivable	26,000	38,000
Prepaid expenses and other current assets	50,667	30,030
Total Current Assets	182,041	519,710
Property and equipment, net	213,818	327,847
Intangible assets, net	832,778	888,950
Security deposit	22,100	22,100
Total Assets	1,250,737	1,758,607
Current Liabilities:
Accounts payable	2,112,219	2,454,944
Accrued expenses and other current liabilities	2,376,299	1,885,551
Accrued interest	333,514	329,166
Current portion of notes payable, net of debt discount of $566,261 and $336,229 at September 30, 2018 and December 31, 2017, respectively	3,151,434	3,467,568
Derivative liabilities	949,957	216,073
Total Current Liabilities	8,923,423	8,353,302
Accrued expenses, non-current portion		38,000
Accrued interest, non-current portion	74,550	9,591
Notespayable, non-current portion, net of debt discount of $20,511 and $1,256 at September 30, 2018 and December 31, 2017,respectively	1,190,911	194,282
Total Liabilities	10,188,884	8,595,175
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 20,000,000 shares; None issued and outstanding at September 30, 2018 and December 31, 2017
Common stock, $0.001 par value; Authorized, 75,000,000 shares; Issued and outstanding 8,721,839 and 6,112,473 shares at September 30, 2018 and December 31, 2017, respectively	8,721	6,112
Additional paid-in capital	51,404,929	44,561,773
Accumulated deficit	(60,351,797)	(51,404,453)
Total Stockholders' Deficiency	(8,938,147)	(6,836,568)
Total Liabilities and Stockholders' Deficiency	$ 1,250,737	$ 1,758,607

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 568,000	$ 336,229
Notes payable non-current, debt discount	$ 18,772	$ 1,256
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares Issued	8,721,839	6,112,473
Common stock, shares Outstanding	8,721,839	6,112,473

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues	$ 26,000	$ 16,000	$ 82,000	$ 43,000
Operating Expenses
Marketing and promotion	155,161	6,988	213,715	45,111
Consulting	417,601	523,917	1,268,485	1,863,361
Research and development	357,436	490,654	1,137,381	1,907,232
General and administrative	284,472	738,077	2,932,162	3,029,318
Total Operating Expenses	1,214,670	1,759,636	5,551,743	6,845,022
Loss From Operations	(1,188,670)	(1,743,636)	(5,469,743)	(6,802,022)
Other Expense
Interest expense	(257,298)	(114,202)	(648,940)	(307,406)
Amortization of debt discount	(540,488)	(159,977)	(1,884,116)	(376,886)
Loss on extinguishment of notes payable, net	(320,383)		(384,171)	(59,938)
Change in fair value of derivative liabilities	(615,322)	(15,311)	(557,274)	(15,311)
Warrant modification expense	(3,100)	(18,962)	(3,100)	(23,462)
Total Other Expense	(1,736,591)	(308,452)	(3,477,601)	(783,003)
Net Loss	$ (2,925,261)	$ (2,052,088)	$ (8,947,344)	$ (7,585,025)
Net Loss Per Share
- Basic and Diluted	$ (0.39)	$ (0.37)	$ (1.32)	$ (1.42)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	7,410,350	5,556,378	6,796,761	5,324,321

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Common Stock [Member]
Balance		$ 6,112
Balance, shares		6,112,473
Shares and warrants issued for cash		$ 70
Shares and warrants issued for cash, shares		70,000
Exercise of warrants for purchase of common stock		$ 207
Exercise of warrants for purchase of common stock, shares		207,084
Shares and warrants issued in satisfaction of accrued services		$ 19
Shares and warrants issued in satisfaction of accrued services, shares		19,000
Conversion of notes payable and accrued interest into common stock		$ 97
Conversion of notes payable and accrued interest into common stock, shares		97,424
Shares and warrants issued in exchange of notes payable and accrued interest		$ 2,107
Shares and warrants issued in exchange of notes payable and accrued interest, shares		2,106,525
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions		$ 74
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions, shares		74,333
Beneficial conversion features related to convertible notes payable
Warrant modifications
Reclassification of derivative liabilities to equity
Stock-based compensation:- common stock		$ 35
Stock-based compensation:- common stock, shares		35,000
Stock-based compensation:- options and warrants
Net loss
Balance	$ 8,721	$ 8,721
Balance, shares	8,721,839	8,721,839
Additional Paid-In Capital [Member]
Balance		$ 44,561,773
Shares and warrants issued for cash		99,930
Exercise of warrants for purchase of common stock		413,961
Shares and warrants issued in satisfaction of accrued services		37,981
Conversion of notes payable and accrued interest into common stock		110,539
Shares and warrants issued in exchange of notes payable and accrued interest		4,338,074
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions		121,379
Beneficial conversion features related to convertible notes payable		69,394
Warrant modifications		3,100
Reclassification of derivative liabilities to equity		105,187
Stock-based compensation:- common stock		52,465
Stock-based compensation:- options and warrants		1,491,146
Net loss
Balance	$ 51,404,929	51,404,929
Accumulated Deficit [Member]
Balance		(51,404,453)
Shares and warrants issued for cash
Exercise of warrants for purchase of common stock
Shares and warrants issued in satisfaction of accrued services
Conversion of notes payable and accrued interest into common stock
Shares and warrants issued in exchange of notes payable and accrued interest
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions
Beneficial conversion features related to convertible notes payable
Warrant modifications
Reclassification of derivative liabilities to equity
Stock-based compensation:- common stock
Stock-based compensation:- options and warrants
Net loss		(8,947,344)
Balance	(60,351,797)	(60,351,797)
Balance		(6,836,568)
Shares and warrants issued for cash		100,000
Exercise of warrants for purchase of common stock		414,168
Shares and warrants issued in satisfaction of accrued services		38,000
Conversion of notes payable and accrued interest into common stock		110,636
Shares and warrants issued in exchange of notes payable and accrued interest		4,340,181
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions		121,453
Beneficial conversion features related to convertible notes payable		69,394
Warrant modifications		3,100
Reclassification of derivative liabilities to equity		105,187
Stock-based compensation:- common stock		52,500
Stock-based compensation:- options and warrants		1,491,146
Net loss	(2,925,261)	(8,947,344)
Balance	$ (8,938,147)	$ (8,938,147)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows From Operating Activities
Net loss	$ (8,947,344)	$ (7,585,025)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	1,884,116	376,886
Accretion of interest expense	427,908	133,431
Depreciation and amortization	183,070	195,191
Stock-based compensation	1,579,046	3,084,753
Loss on extinguishment of note payables, net	384,171	59,938
Loss on settlement of payables		100,895
Change in fair value of derivative liabilities	557,274	15,311
Consulting services provided in exchange for notes payable	131,935
Warrant modification expense	3,100	23,462
Changes in operating assets and liabilities:
Accounts receivable	12,000	(10,000)
Prepaid expenses and other current assets	(20,637)	15,975
Accounts payable	(342,725)	409,992
Accrued interest, expenses and other current liabilities	596,544	685,103
Total Adjustments	5,395,802	5,090,937
Net Cash Used In Operating Activities	(3,551,542)	(2,494,088)
Cash Flows From Investing Activities
Purchases of property and equipment	(12,869)
Net Cash Used In Investing Activities	(12,869)
Cash Flows From Financing Activities
Proceeds from notes payable	3,062,217	1,385,000
Repayments of notes payable	(433,280)	(114,000)
Advances from officers and a family member of an officer	38,500	43,515
Repayments of advances from officers, a director and a family member of an officer	(38,500)	(50,515)
Proceeds from exercise of warrants	414,168	175,000
Sales of common stock and warrants for cash	175,000	1,024,000
Net Cash Provided By Financing Activities	3,218,105	2,463,000
Net Decrease In Cash	(346,306)	(31,088)
Cash - Beginning	451,680	31,822
Cash - Ending	105,374	734
Supplemental Disclosures of Cash Flow Information:
Interest	21,625	11,000
Non-cash investing and financing activities:
Warrant modifications	3,100	23,462
Shares issued and recorded as debt discount in connection with notes payable	121,453	173,439
Shares issued in exchange for notes payable and accrued interest	4,340,181	421,302
Conversion of notes payable and accrued interest into common stock	110,636	389,103
Shares and warrants issued in satisfaction of accrued consulting and director services	38,000	588,592
Reclassification of derivative liabilities to equity	105,187	4,780
Bifurcated embedded conversion options recorded as debt discount	1,938,759	100,309
Beneficial conversion features recorded as debt discount	69,394	10,596
Extinguishments of bifurcated embedded conversion options	1,767,362
Offering costs in accounts payable and accrued expenses		70,907
Consulting services provided in exchange for notes payable	131,935
Sale of warrants recorded as derivative liabilities	$ 75,000

Business Organization and Natur

Business Organization and Nature of Operations	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company” (See Note 3 – Summary of Significant Accounting Policies – Principles of Consolidation). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com BRTX-100 The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of September 30, 2018 and for the three and nine months ended September 30, 2018 and 2017. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the operating results for the full year ending December 31, 2018 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2017 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on April 2, 2018.

Going Concern and Management's

Going Concern and Management's Plans	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2 – Going Concern and Management’s Plans As of September 30, 2018, the Company had a working capital deficiency and a stockholders’ deficiency of $8,741,382 and $8,938,147 respectively. During the three and nine months ended September 30, 2018, the Company incurred net losses of $2,925,261 and $8,947,344, respectively. These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the filing date of this report. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to September 30, 2018, the Company has received aggregate debt financings of $1,138,980, debt (inclusive of accrued interest) of $1,303,023 has been exchanged for common stock, and $191,391 of debt (inclusive of accrued interest and prepayment premiums) has been repaid. As a result, the Company expects to have the cash required to fund its operations through December 2018 while it continues to apply efforts to raise additional capital. While there can be no assurance that it will be successful, the Company is in negotiations to raise additional capital. As of the filing date of this report, the Company has a note payable with a principal balance of $7,500 which is past due.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable, derivative liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Concentrations One license and the related royalties comprised all of the Company’s revenue during the three and nine months ended September 30, 2018 and 2017. See “Revenue Recognition” below. Revenue Recognition The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. In January 2012, the Company and a stem cell treatment company (“SCTC”) entered into a license agreement pursuant to which the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures. Pursuant to the license agreement, the Company granted to the SCTC a non-exclusive sublicense to use certain of the licensed intellectual property in one location outside the United States. Pursuant to an amendment to the license agreement, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the three and nine months ended September 30, 2018, the Company recognized $26,000 and $82,000, respectively, of revenue related to the Company’s sublicenses. During the three and nine months ended September 30, 2017, the Company recognized $16,000 and $43,000, respectively, of revenue related to the Company’s sublicenses. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2018 2017 Options 3,588,451 3,275,700 Warrants 3,413,403 3,644,956 Convertible notes 2,986,487 [1] 509,542 Total potentially dilutive shares 9,988,341 7,430,198 [1] As of September 30, 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 24,710,731 shares of common stock reserved for future note conversions. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) are registered, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Derivative Financial Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) ASC. The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as interest expense over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Multinomial Lattice Model and Black-Scholes Model were used to estimate the fair value of the ECOs of convertible notes payable, warrants and stock options that are classified as derivative liabilities on the unaudited condensed consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments. Sequencing Policy Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. Pursuant to ASC 815, issuance of securities to the Company’s employees or directors are not subject to the sequencing policy. Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The FASB has issued numerous updates that provide clarification on a number of specific issues as well as requiring additional disclosures. The core principle of ASU 2014-09 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance was revised in July 2015 to be effective for emerging growth companies for annual and interim periods beginning on or after December 15, 2018. The Company expects to adopt ASU 2014-09 using a modified retrospective approach on January 1, 2019. The Company has completed an analysis and preliminarily concluded that the adoption of ASU 2014-09 will not have an impact on the Company’s financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718)” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods within those annual periods, beginning after December 15, 2017, for share-based payment awards modified on or after the adoption date. The adoption of this standard did not have a material impact on the Company’s financial statement disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718),” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the unaudited condensed consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-09, “Codification Improvements” (“ASU 2018-09”). These amendments provide clarifications and corrections to certain ASC subtopics including the following: Income Statement - Reporting Comprehensive Income – Overall (Topic 220-10), Debt - Modifications and Extinguishments (Topic 470-50), Distinguishing Liabilities from Equity – Overall (Topic 480-10), Compensation - Stock Compensation - Income Taxes (Topic 718-740), Business Combinations - Income Taxes (Topic 805-740), Derivatives and Hedging – Overall (Topic 815-10), and Fair Value Measurement – Overall (Topic 820-10). The majority of the amendments in ASU 2018-09 will be effective in annual periods beginning after December 15, 2018. The Company is currently evaluating and assessing the impact this guidance will have on its unaudited condensed consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”). The amendments in ASU 2018-10 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) and have the same effective and transition requirements as ASU 2016-02. Upon the effective date, ASU 2018-10 will supersede the current lease guidance in ASC Topic 840, Leases. Under the new guidance, lessees will be required to recognize for all leases, with the exception of short-term leases, a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis. Concurrently, lessees will be required to recognize a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2018-10 is effective for emerging growth companies for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The guidance is required to be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative periods presented in the financial statements. The Company is currently assessing the impact this guidance will have on its unaudited condensed consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements,” (“ASU 2018-11”). The amendments in ASU 2018-11 related to transition relief on comparative reporting at adoption affect all entities with lease contracts that choose the additional transition method and separating components of a contract affect only lessors whose lease contracts qualify for the practical expedient. The amendments in ASU 2018-11 are effective for emerging growth companies for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is currently assessing the impact this guidance will have on its unaudited condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements associated with fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its condensed consolidated financial statements.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2018
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: September 30, 2018 December 31, 2017 Accrued payroll and other accrued expenses $ 347,680 $ 350,173 Accrued research and development expenses 626,175 636,175 Accrued general and administrative expenses 930,482 604,308 Accrued director compensation 432,500 282,500 Deferred rent 39,462 50,395 Total accrued expenses 2,376,299 1,923,551 Less: accrued expenses, current portion 2,376,299 1,885,551 Accrued expenses, non-current portion $ - $ 38,000 See Note 6 - Commitments and Contingencies for additional details regarding the exchange of accrued consulting fees for common stock and a warrant.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Notes Payable	Note 5 – Notes Payable A summary of the notes payable activity during the nine months ended September 30, 2018 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2017 $ 845,000 $ 2,029,870 [1] $ 1,124,465 $ (337,485 ) $ 3,661,850 Issuances - 3,800,728 [2] 128,000 - 3,928,728 Exchanges for equity (95,000 ) (1,600,676 ) (542,760 ) 55,673 (2,182,763 ) Conversions to equity - (105,000 ) - - (105,000 ) Repayments (30,000 ) (403,280 ) - 24,973 (408,307 ) Extinguishment of notes payable - (407,295 )[2] - - (407,295 ) Recognition of debt discount - - - (2,456,892 ) (2,456,892 ) Accretion of interest expense - 7,782 177,283 242,843 427,908 Amortization of debt discount - - - 1,884,116 1,884,116 Outstanding, September 30, 2018 $ 720,000 $ 3,322,129 [1][3] $ 886,988 $ (586,772 ) $ 4,342,345 [1] As of September 30, 2018 and December 31, 2017, a portion of convertible notes with an aggregate principal balance of $1,202,693 and $1,777,788, respectively, was currently convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of September 30, 2018 and December 31, 2017, a portion of convertible notes with an aggregate principal balance of $0 and $252,082, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised that conversion right, the respective holder had the right to accelerate the conversion of up to $0 and $196,666 of principal into shares of common stock at September 30, 2018 and December 31, 2017, respectively, at the same conversion price. [2] During the nine months ended September 30, 2018, convertible notes in the aggregate principal amount of $407,295 were issued concurrently with the extinguishment of certain convertible notes payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other for additional details. [3] As of September 30, 2018, outstanding convertible notes in the aggregate principal amount of $80,000 were past maturity. See Note 9 – Subsequent Events for details regarding the exchange of such aggregate principal amount. As of September 30, 2018, a portion of convertible notes with an aggregate principal balance of $2,119,436, which are not currently convertible, will become convertible subsequent to September 30, 2018 into shares of the Company's common stock at the election of the respective holder. Related Party Notes As of September 30, 2018 and December 31, 2017, related party notes consisted of notes payable issued to certain directors of the Company, family members of an officer of the Company, and the Tuxis Trust (the “Trust”). A director and principal shareholder of the Company serves as a trustee of Trust, which was established for the benefit of his immediate family. During the nine months ended September 30, 2018, the Company partially repaid certain related party notes in the aggregate principal amount of $30,000. During the nine months ended September 30, 2018, the Company and certain related parties agreed to exchange certain notes with an aggregate principal balance of $95,000 for an aggregate of 76,000 shares of the Company’s common stock at $1.25 per share. The common stock had an aggregate exchange date value of $114,000 and, as a result, the Company recorded a loss on extinguishment of notes payable of $19,000. During the nine months ended September 30, 2018, the Company and certain related parties agreed to extend the maturity dates of notes payable with an aggregate principal balance of $140,000 from maturity dates ranging between August 2016 to February 2018 to new maturity dates ranging from July 2018 to December 2018. Convertible Notes Issuances During the nine months ended September 30, 2018, the Company issued certain lenders and a consultant convertible notes payable in the aggregate principal amount of $3,393,433 for aggregate cash proceeds of $2,952,213. The difference of $441,220 was recorded as follows: (i) $309,285 was recorded as a debt discount and will be amortized over the terms of the respective notes and (ii) $131,935 was immediately recognized as consulting expense in the condensed consolidated financial statements. The convertible notes bear interest at rates ranging between 6% to 12% per annum payable at maturity with original maturity dates ranging between June 2018 through September 2019. See Note 6 – Commitments and Contingencies for additional details regarding convertible notes issued in connection with consulting services. As of September 30, 2018, convertible notes in the aggregate principal amount of $407,295 were issued concurrently with the extinguishment of certain convertible notes payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other for additional details. The above described convertible notes in the aggregate principal amount of $3,800,728 are convertible as follows: (i) $1,351,293 of aggregate principal and the respective interest is convertible into shares of the Company’s common stock at the election of the respective holder at any time immediately on or after the issue dates until the respective balances have been paid in full, (ii) $2,262,500 of aggregate principal and the respective interest is convertible into shares of the Company’s common stock at the election of the respective holder after the 180th day following the respective issue date until the balance has been paid in full, (iii) $55,000 of principal and respective interest is convertible into shares of the Company’s stock at the election of the Company during the five days prior to maturity and ending on the day immediately prior to maturity; however, should the Company elect to convert any portion of the $55,000 of note principal and respective accrued interest, the holder would have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price, and (iv) $170,000 ($131,935 earned as of September 30, 2018) of aggregate principal and the respective interest is convertible from time to time following the respective issue date at the holder’s election. See Note 6 – Commitments and Contingencies for additional details regarding convertible notes issued in connection with consulting services. During the nine months ended September 30, 2018, convertible note issuances were comprised of (i) $675,000 of convertible notes that were convertible at a fixed price of $2.00 per share for the first six months following the respective issue date, thereafter, at a conversion price equal to the greater of (a) 58% of the fair value of the Company’s stock or (b) $0.10 per share, until the respective note has been paid in full, (ii) $978,228 of convertible notes that were convertible at the greater of (a) a range between 50% to 65% of the fair value of the Company’s stock or (b) $0.75 or $1.00 per share, depending on the note, (iii) $350,000 of convertible notes that were convertible at a fixed conversion price of $2.15 per share and (iv) $1,797,500 of convertible notes that were convertible at 58% of the fair value of the Company’s stock. In connection with the issuance of certain convertible notes, the Company issued the lenders an aggregate of 28,333 shares of the Company’s common stock and the relative fair value of $42,827 was recorded as debt discount and is being amortized over the term of the respective notes. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other and Note 8 – Derivative Liabilities for additional details regarding the ECOs of the convertible notes. Of the convertible notes issued during the nine months ended September 30, 2018, convertible notes in the aggregate principal amount of $137,500 have mandatory prepayment terms at the option of the holder (“MPOs”). Convertible notes issued with MPOs permit the respective holder to demand prepayment of the note, in cash, at a premium of 35% of the then outstanding principal balance and accrued interest during the period between 150 days to 179 days following the respective issuance date. Of the convertible notes issued during the nine months ended September 30, 2018, convertible notes in the aggregate principal amount of $2,811,500 have prepayment premiums. In the event that the Company elects to prepay certain notes during the first ninety-day period following the issue date, the respective holder is entitled to receive a prepayment premium of up to 30%, depending on the note, on the then outstanding principal balance including accrued interest. In the event that the Company prepays any of the notes during the second ninety-day period following the issue date, the respective holder is entitled to receive a prepayment premium of up to 40%, depending on the note, on the then outstanding principal balance including accrued interest. In the event that the Company prepays a certain note after the 180 th Of the convertible notes issued during the nine months ended September 30, 2018, convertible notes in the aggregate principal amount of $1,756,500 have most favored nation (“MFN”) provisions, whereby, so long as such respective note is outstanding, upon any issuance by the Company of any security with conversion discounts, conversion lookback periods, floor prices, lookback formulas, and/or prepayment premiums, depending on the note, more favorable to the holder of such security, then at the respective holder’s option, those more favorable terms shall become a part of the transaction documents with the holder. As of September 30, 2018, notes with MFN provisions were convertible using MFN conversion terms equal to conversion prices ranging between 58%-65% of the fair market value of the Company’s stock, as defined. Conversions, Exchanges and Other During the nine months ended September 30, 2018, the Company and certain lenders exchanged certain convertible notes with bifurcated ECOs with an aggregate principal balance of $1,600,676 and aggregate accrued interest of $100,503 for an aggregate of 1,579,032 shares of the Company’s common stock at prices ranging from $0.83 to $2.38 per share. The common stock had an aggregate exchange date value of $3,548,942 and, as a result, the Company recorded a loss on extinguishment of notes payable of $77,132. As a result of the exchanges, an aggregate of $1,826,304 and $55,673 of the related ECOs and debt discounts were extinguished, respectively. See Note 8 – Derivative Liabilities for additional details. During the nine months ended September 30, 2018, the Company elected to convert certain convertible notes with an aggregate principal balance of $105,000 and aggregate accrued interest of $5,637 into an aggregate of 97,424 shares of the Company’s common stock at conversion prices ranging from $0.82 to $2.02 per share. During the nine months ended September 30, 2018, the Company repaid an aggregate principal amount of $403,280 of convertible notes payable, $21,625 of the respective aggregate accrued interest and an aggregate of $81,709 of prepayment premiums. As a result of the repayments, the Company recorded a loss on extinguishment of notes payable of $106,682 and an aggregate of $24,973 of the related debt discounts were extinguished. During the nine months ended September 30, 2018, the Company and certain lenders agreed to multiple extensions of the maturity dates of notes payable with an aggregate principal balance of $681,445 from maturity dates ranging between December 2017 to July 2018 to new maturity dates ranging from April 2018 to September 2018. In consideration of the extensions, the Company issued a lender 4,500 shares of the Company’s common stock. The issuance date fair value of the common stock of $9,000 was recorded as debt discount and is being amortized over the term of the note. See below within this Note 5 – Notes Payable – Conversions, Exchanges and Other and Note – 8 Derivative Liabilities for additional details regarding the ECOs of the convertible notes. As of September 30, 2018, there were $80,000 of convertible notes payable past due. During the nine months ended September 30, 2018, a lender to the Company acquired three convertible promissory notes issued by the Company in the aggregate outstanding amount of $407,295 (inclusive of accrued interest of $7,782) from a different lender to the Company. The Company exchanged the acquired notes for new convertible notes in the aggregate principal amount of $407,295 which accrue interest at a rate of 8% per annum, payable on the maturity date of August 30, 2019. Additionally, the conversion terms of the acquired notes were modified such that the new notes are convertible, at the option of holder, into shares of common stock of the Company at a conversion price equal to the greater of (a) 65% (previously 80%) of fair value of the Company’s common stock or (b) $0.10 per share (previously $1.00 per share). The ECOs of the notes were subject to sequencing and their issuance date fair value of $260,377 was accounted for as a derivative liability (See Note 8 – Derivative Liabilities for additional details). Since the fair value of the new ECO exceeded 10% of the principal amount of the new notes, the note exchanges were accounted for as extinguishments, and accordingly the Company recognized a net loss on extinguishment of $58,942 in connection with the derecognition of the net carrying amount of $608,730 of the extinguished debt ($407,295 of aggregate principal and interest and the derivative liability carrying value of their ECOs of an aggregate of $201,435) and the issuance of the new convertible notes in the aggregate principal amount $407,295 plus the fair value of the new notes’ ECOs of an aggregate of $260,377. During the nine months ended September 30, 2018, the Company determined that certain ECOs of issued or extended convertible notes were derivative liabilities. The aggregate issuance date value of the bifurcated ECOs was $2,199,136, of which $1,938,759 was recorded as a debt discount and is being amortized over the terms of the respective convertible notes and $260,377 was recognized as part of an extinguishment loss as described above. See Note 8 – Derivative Liabilities for additional details. During the nine months ended September 30, 2018 and 2017, the contingently adjustable non-bifurcated, beneficial conversion features associated with certain convertible notes were resolved and such notes became convertible during the period. The Company estimated the intrinsic value of the beneficial conversion features based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the adjusted conversion price embedded in the convertible note. During the nine months ended September 30, 2018 and 2017, the Company recognized $69,394 and $10,596, respectively, related to the beneficial conversion feature as debt discount which was immediately amortized. Other Notes During the nine months ended September 30, 2018, the Company issued a lender three-month notes payable in the aggregate principal amount of $128,000, which bear no interest, for aggregate cash proceeds of $110,000. The $18,000 difference was recorded as debt discount and is being amortized over the terms of the respective notes. In connection with the issuances of the promissory notes, the Company issued the lender an aggregate of 6,500 shares of the Company’s common stock. The issuance date fair value of the common stock of $9,627 was recorded as debt discount and is being amortized over the terms of the respective notes. During the nine months ended September 30, 2018, the Company and certain lenders agreed to exchange certain notes with an aggregate principal balance of $542,760 and aggregate accrued interest of $12,064 for an aggregate of 451,493 shares of the Company’s common stock at prices ranging from $1.00 to $1.50 per share. The common stock had an aggregate exchange date value of $677,239 and, as a result, the Company recorded a loss on extinguishment of notes payable of $122,415. During the nine months ended September 30, 2018, the Company and certain lenders agreed to multiple extensions of the maturity dates of notes payable with an aggregate principal balance of $1,309,747 from maturity dates ranging between December 2017 to October 2018 to new maturity dates ranging from March 2018 to January 2019. In consideration of the extensions, the Company issued certain lenders an aggregate of 35,000 shares of the Company’s common stock. The aggregate issuance date fair value of the common stock of $60,000 was recorded as debt discount and is being amortized over the terms of the respective notes. Additionally, in connection with a certain extension, the Company increased the stated rate at which the note bears interest, from 0% to 8% per annum, effective June 2018. As of September 30, 2018, the only note that was past due was a convertible note and is referenced within Note 5 – Notes Payable – Convertible Notes.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Consulting Agreements In January 2018, a February 2011 agreement for business advisory services that had expired on December 31, 2017 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of January 1, 2018 and provides for an expiration date of December 31, 2018. In consideration of the extension of the term of the consulting agreement, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 30,000 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate grant date value of the warrant of $48,192 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. Concurrently, the Company and the consultant agreed to exchange $38,000 of accrued consulting fees for 19,000 shares of common stock of the Company and a two-year warrant for the purchase of 4,750 shares of common stock of the Company at an exercise price of $4.00 per share, whose combined value is consistent with the carrying value of the liabilities being satisfied. On July 10, 2018, as further amended on August 22, 2018, the Company entered into consulting agreement with a consultant for services through December 31, 2018. In consideration of the consulting services, the Company issued the consultant convertible notes in the aggregate principal amount of $170,000 which will be earned and recognized ratably over their respective consulting agreement term. As of September 30, 2018, the Company has recorded an aggregate $131,935 of marketing and promotion expense for services rendered with a corresponding credit to notes payable. The notes mature at dates between January 2019 and February 2019 and bear interest at the rate of 10% per annum, payable at maturity. Pursuant to the notes, the holder has the right, from time to time following the respective issue date, at its election, to convert all or part of the outstanding and earned principal and accrued interest into shares of common stock of the Company, at a price equal to the greater of (a) $0.10 per share, or (b) the lesser of (i) $1.75 per share and (ii) 65% of the fair market value of the Company’s common stock, as defined. The Company may prepay the notes prior to the maturity date provided the principal is prepaid in full, plus interest, plus a prepayment premium of 25% on the principal. In July 2018, the Company and a consultant agreed to further extend a previously expired consulting agreement from May 2018 to December 2018. In consideration of the extension of the term of the consulting agreement, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 35,000 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate grant date value of the warrant of $43,106 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. Scientific Advisory Services In July 2018, the Company entered into an agreement with a consultant to serve as a member of its Scientific Advisory Board and provide advice and guidance in connection with scientific matters relating to the Company’s business. The agreement will continue until terminated by either party for any reason upon ten days written notice. In connection with the agreement, the Company issued the advisor a five-year option to purchase up to 25,000 shares of the Company’s common stock at an exercise price of $1.70 per share. The options vest as follows: (i) 12,500 vest immediately and (ii) 12,500 vest on the one-year anniversary of the grant date. The option was subject to the Company’s sequencing policy and, as a result, the grant date fair value of the option of $35,400 was immediately recognized as stock based-compensation expense and recorded as a derivative liability. See Note 8 – Derivative Liabilities for additional details. In addition, on each one-year anniversary of the agreement date (as long as the consultant remains engaged), options to purchase an additional 5,000 shares are to be granted to the consultant which shall be exercisable for a period of five years from the respective dates of grant at exercise prices equal to the fair market value of the Company’s common stock. Operating Lease Rent expense amounted to approximately $31,000 and $92,000 for the three and nine months ended September 30, 2018, respectively. Rent expense amounted to approximately $32,000 and $96,000 for the three and nine months ended September 30, 2017, respectively. Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business, and as of September 30, 2018, none are expected to materially impact the Company’s financial position. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements In January 2018, the Company entered into an employment agreement with its new Senior Vice President of Planning and Business Development (the “Senior VP”). Pursuant to the employment agreement, in the event of the termination of the Senior VP’s employment by the Company without “cause” or the resignation by the Senior VP for “good reason” (each as defined in the employment agreement), the Senior VP would be entitled to receive severance in an amount equal to three months of his then annual base salary. See Note 9 – Subsequent Events for details regarding the Senior VP’s resignation. In March 2018, the Company and its CEO agreed to an extension of the expiration date of his employment agreement from June 30, 2018 to December 31, 2019. In connection with the extension, the CEO is entitled to new performance-based cash bonuses payable for the years ending December 31, 2018 and 2019, such that an aggregate of up to 50% of the CEO’s then annual base salary per annum could be earned for such year pursuant to the satisfaction of such goals. As of September 30, 2018 and December 31, 2017, the Company accrued approximately $68,000 and $87,000, respectively, for 2016 bonus milestones which were achieved but remain unpaid. In May 2018, the Company’s Compensation Committee and Board of Directors, respectively, approved the new performance-based cash bonuses payable for the year ending December 31, 2018 for certain of the Company’s officers and employees, such that together with the CEO, an aggregate of up to $400,938 could be earned for 2018 pursuant to the satisfaction of such goals. As of September 30, 2018, the Company accrued approximately $178,000 for 2018 bonus milestones which were probable to be achieved.

Stockholders' Deficiency

Stockholders' Deficiency	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the nine months ended September 30, 2018 and 2017. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Common Stock and Warrant Offering During the nine months ended September 30, 2018, the Company issued an aggregate of 70,000 shares of the Company’s common stock and five-year immediately vested warrants to purchase an aggregate of 70,000 shares of the Company’s common stock at an exercise price of $3.50 per share to certain investors for aggregate gross proceeds of $175,000. The warrants had an aggregate issuance date fair value of $87,300, of which $75,000 was recorded as derivative liabilities in connection with the Company’s sequencing policy. See Note 8 – Derivative Liabilities for additional details. Compensatory Common Stock Issuance During the three and nine months ended September 30, 2018, the Company issued 35,000 shares of immediately vested common stock valued at $52,500 to a consultant for services rendered. During the three and nine months ended September 30, 2017, the Company issued 10,000 shares of immediately vested common stock valued at $20,000 to a consultant for services rendered. Stock Warrants Warrant Compensation See Note 6 - Commitments and Contingencies for additional details associated with the issuance of common stock and warrants in connection with consulting agreement extensions. The Company recorded stock–based compensation expense of $43,105 and $91,297 for the three and nine months ended September 30, 2018, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the unaudited condensed consolidated statements of operations. For the three and nine months ended September 30, 2017, the Company recorded stock–based compensation expense of $40,275 and $111,478, respectively, related to stock warrants issued as compensation. Warrant Modifications and Exercises During the nine months ended September 30, 2018, the Company issued an aggregate of 207,084 shares of the Company’s common stock pursuant to the exercise of warrants for aggregate gross proceeds of $414,168. The shares were issued pursuant to a warrant repricing program under which the exercise price for certain outstanding and exercisable warrants for the purchase of shares of common stock of the Company was reduced to $2.00 per share (reduced from exercise prices ranging from $4.00 to $5.00 per share). The warrants were exercised over a limited period of time. In connection with the share issuances, the Company issued to the purchasers of such shares additional two-year warrants for the purchase of an aggregate of 51,771 shares of common stock of the Company at an exercise price of $4.00 per share. The Company did not recognize a warrant modification charge as there was no incremental value of the modified warrants and additional warrants issued as compared to the original warrants, both valued as of the respective modification dates. During the nine months ended September 30, 2018, the Company reduced the exercise price and extend the expiration date of a certain warrant held by an investor for the purchase of 10,000 shares of common stock of the Company. The exercise price of the warrant was reduced from an exercise price of $5.00 per share to $4.00 per share and the expiration date of the warrant was extended from an expiration date in May 2021 to a new expiration date in May 2023. The Company recognized a warrant modification charge of $3,100, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates which is reflected in warrant modification expense in the unaudited condensed consolidated statement of operations. Warrant Activity Summary In applying the Black-Scholes option pricing model to warrants granted or issued, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate 2.73% - 2.83 % 1.99% - 2.14 % 1.92% - 2.83 % 1.98% - 2.33 % Contractual term (years) 5.00 5.00 1.98 - 5.00 5.00 Expected volatility 139 % 130 % 128% - 139 % 120% - 132 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and nine months ended September 30, 2018 was approximately $1.24 and $1.23 per share, respectively. The weighted average estimated fair value of the warrants granted during the three and nine months ended September 30, 2017 was approximately $1.54 and $1.60 per share, respectively. A summary of the warrant activity during the nine months ended September 30, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2017 3,435,134 $ 4.47 Issued 191,521 3.82 Exercised (207,084 ) 2.00 Expired (6,168 ) 44.92 Outstanding, September 30, 2018 3,413,403 $ 4.33 2.1 $ - Exercisable, September 30, 2018 3,413,403 $ 4.33 2.1 $ - The following table presents information related to stock warrants at September 30, 2018: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $3.50 - $3.99 70,000 4.8 70,000 $4.00 - $4.99 3,024,079 2.0 3,024,079 $5.00 - $5.99 195,989 2.7 195,989 $6.00 - $7.99 40,000 1.8 40,000 $8.00 - $9.99 2,500 1.2 2,500 $10.00 - $14.99 40,400 1.5 40,400 $15.00 - $19.99 35,435 0.9 35,435 $20.00 - $40.00 5,000 0.2 5,000 3,413,403 2.1 3,413,403 Stock Options In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate 2.74 % 1.78% - 1.88 % 2.44% - 2.74 % 1.77% - 1.88 % Expected term (years) 5.01 6.00 5.00 - 9.69 5.50 - 6.00 Expected volatility 139 % 130 % 129% - 139 % 120% - 130 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the stock options granted during the three and nine months ended September 30, 2018 was approximately $1.42 and $2.92 per share, respectively. The weighted average estimated fair value of the stock options granted during the three and nine months ended September 30, 2017 was approximately $2.54 and $2.75 per share, respectively. In January 2018, the Company granted a ten-year option to a consultant of the Company to purchase 10,000 shares of the Company’s common stock at an exercise price of $3.20 per share. The options vest ratably over three years on the issuance date anniversaries. The option had an aggregate grant date value of $33,700. During the three months ended March 31, 2018, the option was forfeited in connection with the consultant’s termination and accordingly, no expense related to the option was recognized. In January 2018, the Company granted the Senior VP a ten-year option to purchase 500,000 shares of the Company’s common stock at an exercise price of $3.40 per share. The option grant provided for vesting based upon the achievement of a certain performance condition. The grant date value of the option was $1,491,300, which is recognizable to the extent such milestone is deemed probable to occur. See Note 9 – Subsequent Events for additional details regarding the Senior VP’s resignation. See Note 6 - Commitments and Contingencies for details associated with the issuance of a stock option in connection with the Company entering into an agreement with a consultant to serve as a member of its Scientific Advisory Board. A summary of the option activity during the nine months ended September 30, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2017 3,122,202 $ 4.25 Granted 535,000 3.32 Forfeited (68,751 ) 4.01 Outstanding, September 30, 2018 3,588,451 $ 4.12 7.5 $ 1,250 Exercisable, September 30, 2018 2,590,627 $ 4.43 6.9 $ 625 The following table presents information related to stock options at September 30, 2018: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $1.70 - $2.99 218,500 8.2 77,003 $3.00 - $3.99 2,127,000 8.1 1,278,673 $4.00 - $4.99 1,165,451 5.7 1,157,451 $5.00 - $5.99 5,000 5.7 5,000 $6.00 - $19.99 37,500 5.3 37,500 $20.00 - $30.00 35,000 3.5 35,000 3,588,451 6.9 2,590,627 The following table presents information related to stock option expense: Weighted Average For the For the Remaining Three Months Ended Nine Months Ended Unrecognized at Amortization September 30, September 30, September 30, Period 2018 2017 2018 2017 2018 (Years) Consulting $ 163,757 $ 301,622 $ 669,574 $ 1,284,781 $ 400,486 0.7 Research and development 98,148 157,960 242,586 522,883 289,070 1.5 General and administrative (488,463 ) 281,785 523,089 1,145,611 1,812,016 0.4 $ (226,558 ) $ 741,367 $ 1,435,249 $ 2,953,275 $ 2,501,572 0.6

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 8 – Derivative Liabilities The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Beginning balance as of January 1, 2018 $ 216,073 Issuance of derivative liabilities 2,309,536 Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges (2,027,739 ) Change in fair value of derivative liabilities 557,274 Reclassification of derivative liabilities to equity (105,187 ) Ending balance as of September 30, 2018 $ 949,957 In applying the Multinomial Lattice and Black-Scholes option pricing models to derivatives issued and outstanding during the nine months ended September 30, 2018, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate 1.93% - 2.94 % 1.30% - 1.34 % 1.22% - 2.94 % 1.30% - 1.34 % Expected term (years) 0.25 - 5.00 0.75 - 0.91 0.25 - 5.00 0.75 - 0.91 Expected volatility 120% - 208 % 111% - 133 % 100% - 208 % 111% - 133 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % During the nine months ended September 30, 2018, the Company recorded new derivative liabilities in the aggregate amount of $2,199,136, $75,000 and $35,400 related to the ECOs of certain convertible notes payable, warrants and stock options effected by sequencing, respectively. See Note 5 – Notes Payable – Convertible Notes and Other Notes for additional details. See Note 6 – Commitments and Contingencies for a stock option issued and deemed to be a derivative liability. See Note 7 – Stockholders’ Deficiency for warrants issued and deemed to be derivative liabilities. During the nine months ended September 30, 2018, the Company extinguished an aggregate of $2,027,739 of derivative liabilities in connection with repayments, conversions and exchanges of certain convertible notes payable into shares of the Company’s common stock. See Note 5 – Notes Payable – Convertible Notes and Other Notes for additional details. During the nine months ended September 30, 2018, the Company reclassified an aggregate of $105,187 of derivative liabilities to equity as a result of a change in the sequencing status. On September 30, 2018, the Company recomputed the fair value of ECOs recorded as derivative liabilities to be $760,821. The Company recorded a loss on the change in fair value of these derivative liabilities of $579,772 and $558,552 for the three and nine months ended September 30, 2018, respectively. On September 30, 2018, the Company recomputed the fair value of the derivative liabilities related to outstanding warrants to be $152,017. These warrants are either redeemable for cash equal to the Black-Scholes value, as defined, at the election of the warrant holder upon a fundamental transaction pursuant to the warrant terms or were issued subsequent to the commencement of sequencing. The Company recorded a loss on the change in fair value of these derivative liabilities of $33,831 during the three months ended September 30, 2018 and a gain on the change in fair value of these derivative liabilities of $2,997 during the nine months ended September 30, 2018. On September 30, 2018, the Company recomputed the fair value of the derivative liabilities related to an outstanding consultant stock option to be $37,119. The stock option was issued subsequent to the commencement of sequencing. The Company recorded a loss on the change in fair value of these derivative liabilities of $1,719 during the three and nine months ended September 30, 2018.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events Employment Agreements Former Senior VP In October 2018, the Senior VP resigned from the Company (the “Former Senior VP”). The Former Senior VP is entitled to any accrued unpaid salary and unused vacation days as well as any accrued unpaid bonus that may be payable to him through his termination date pursuant to his employment agreement. Additionally, the Former Senior VP’s unvested option to purchase 500,000 shares was forfeited as of the termination date. Executive Vice President In October 2018, the Company entered into an employment agreement with its new Executive Vice President and Chief Strategy Officer (the “Executive VP”). Pursuant to the employment agreement, in the event of the termination of the Executive VP’s employment by the Company without cause or the resignation by the Executive VP for good reason (each as defined in the employment agreement) the Executive VP would be entitled to receive severance in an amount equal to six months of his then annual base salary. Additionally, in connection with the employment agreement, the Executive VP was granted a ten-year option to purchase up to 500,000 shares of the Company’s common stock at an exercise price of $1.42 per share. The option vests as follows: (i) 100,000 options vested immediately, (ii) 150,000 options vest upon the earlier of (a) the achievement of a certain performance condition or (b) the first anniversary of the issuance date, and (iii) 250,000 options vest on the second anniversary of the date of grant. The grant date value of the option will be recognized over the respective expected vesting period. Scientific Advisory Services In October 2018, the Company entered into an agreement with a consultant to serve as Chairman of the Disc Committee of its Scientific Advisory Board (the “Disc Committee Chairman”) and provide advice and guidance in connection with scientific matters relating to the Company’s business. The agreement will continue until terminated by either party for any reason upon thirty days written notice. In connection with the agreement, the Company issued the Disc Committee Chairman a ten-year option to purchase up to 75,000 shares of the Company’s common stock at an exercise price of $1.80 per share. The option vests as follows: (i) 25,000 vest immediately and (ii) 50,000 vest upon the achievement of certain performance conditions. The grant date value of the option will be recognized over the respective expected vesting period. Stock Options Subsequent to September 30, 2018, the Company issued ten-year options to employees, directors and Scientific Advisory Board members of the Company to purchase an aggregate of 995,000 shares of common stock of the Company at an exercise price of $1.23 per share. The options vest as follows: (i) 216,667 options vested immediately, (ii) 331,671 options vest on the one-year anniversary of the respective issuance date, (iii) 331,666 options vest on the two-year anniversary of the respective issuance date, and (iv) 114,996 options vest on the three-year anniversary of the respective issuance date. The grant date value of the options will be recognized over the respective expected vesting period. Stock Warrants Subsequent to September 30, 2018, the Company issued to a consultant an immediately vested five-year warrant for the purchase of 75,000 shares of common stock of the Company at an exercise price of $2.00 per share for services rendered. The aggregate grant date value of the warrant will be recognized immediately as stock-based compensation expense. Notes Payable Subsequent to September 30, 2018, in consideration of consulting services to be performed, the Company issued the consultant a convertible note in the principal amount of $90,000. The note matures in April 2019 and bears interest at the rate of 10% per annum, payable at maturity. Pursuant to the note, the holder has the right, at its election, at certain times, to convert all or part of the outstanding and earned principal and accrued interest into shares of common stock of the Company at a price generally equal to the lesser of (i) $1.27 per share or (ii) 65% of the fair market value of the Company’s common stock. The Company may prepay the note prior to the maturity date provided the principal is prepaid in full, plus interest, plus a prepayment premium of 25% on the principal. Subsequent to September 30, 2018, in addition to the convertible note described above, the Company issued convertible promissory notes in the aggregate principal amount of $1,230,000 for aggregate cash proceeds of $1,138,980. The convertible notes bear interest at a rate of 12% per annum payable at maturity with original maturity dates ranging between April 2019 to October 2019. The convertible notes are convertible as follows: (i) $880,000 of aggregate principal and the respective accrued interest is convertible into shares of the Company's common stock at the election of the holder after the 180th day following the issue date at a conversion price equal to 58% of the fair value of the Company's common stock and (ii) $350,000 of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the holder at any time immediately on or after the issue date until the balance has been paid in full at a conversion price equal to 58% of the fair value of the Company's common stock. In connection with the issuances of certain convertible promissory notes in the aggregate principal amount of $635,000, the Company issued to certain lenders an aggregate of 24,916 shares of common stock of the Company. The issuance date fair value of the common stock will be recorded as a debt discount and will be amortized over the terms of the respective notes. In the event that the Company elects to prepay any of the respective notes during the first ninety-day period following the issue date, the holder is entitled to receive a prepayment premium of up to 35%, depending on the note, of the then outstanding principal balance plus accrued interest. In the event that the Company elects to prepay any of the notes during the second ninety-day period following the issue date, the holder is entitled to receive a prepayment premium up to 40%, depending on the note, of the then outstanding principal balance plus accrued interest. Of the aforementioned note issuances, a certain note in the principal amount of $55,000 may be redeemed, in cash, at a premium of 35% of the then outstanding principal and balance and accrued interest during the period between 150 days to 179 days following the respective issuance date. Subsequent to September 30, 2018, the Company and certain lenders agreed to exchange an aggregate principal amount of $1,211,422 and aggregate accrued interest of $91,601 of certain convertible notes payable for an aggregate of 1,707,181 shares of the Company’s common stock at prices ranging from $0.59 to $1.01 per share. Subsequent to September 30, 2018, the Company repaid an aggregate principal amount of $135,022 of convertible notes payable, $6,749 of the respective aggregate accrued interest and an aggregate of $49,620 of prepayment premiums.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable, derivative liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations	Concentrations One license and the related royalties comprised all of the Company’s revenue during the three and nine months ended September 30, 2018 and 2017. See “Revenue Recognition” below.
Revenue Recognition	Revenue Recognition The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. In January 2012, the Company and a stem cell treatment company (“SCTC”) entered into a license agreement pursuant to which the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures. Pursuant to the license agreement, the Company granted to the SCTC a non-exclusive sublicense to use certain of the licensed intellectual property in one location outside the United States. Pursuant to an amendment to the license agreement, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the three and nine months ended September 30, 2018, the Company recognized $26,000 and $82,000, respectively, of revenue related to the Company’s sublicenses. During the three and nine months ended September 30, 2017, the Company recognized $16,000 and $43,000, respectively, of revenue related to the Company’s sublicenses.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2018 2017 Options 3,588,451 3,275,700 Warrants 3,413,403 3,644,956 Convertible notes 2,986,487 [1] 509,542 Total potentially dilutive shares 9,988,341 7,430,198 [1] As of September 30, 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 24,710,731 shares of common stock reserved for future note conversions.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) are registered, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) ASC. The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as interest expense over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Multinomial Lattice Model and Black-Scholes Model were used to estimate the fair value of the ECOs of convertible notes payable, warrants and stock options that are classified as derivative liabilities on the unaudited condensed consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments.
Sequencing Policy	Sequencing Policy Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. Pursuant to ASC 815, issuance of securities to the Company’s employees or directors are not subject to the sequencing policy.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The FASB has issued numerous updates that provide clarification on a number of specific issues as well as requiring additional disclosures. The core principle of ASU 2014-09 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance was revised in July 2015 to be effective for emerging growth companies for annual and interim periods beginning on or after December 15, 2018. The Company expects to adopt ASU 2014-09 using a modified retrospective approach on January 1, 2019. The Company has completed an analysis and preliminarily concluded that the adoption of ASU 2014-09 will not have an impact on the Company’s financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718)” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods within those annual periods, beginning after December 15, 2017, for share-based payment awards modified on or after the adoption date. The adoption of this standard did not have a material impact on the Company’s financial statement disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718),” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the unaudited condensed consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-09, “Codification Improvements” (“ASU 2018-09”). These amendments provide clarifications and corrections to certain ASC subtopics including the following: Income Statement - Reporting Comprehensive Income – Overall (Topic 220-10), Debt - Modifications and Extinguishments (Topic 470-50), Distinguishing Liabilities from Equity – Overall (Topic 480-10), Compensation - Stock Compensation - Income Taxes (Topic 718-740), Business Combinations - Income Taxes (Topic 805-740), Derivatives and Hedging – Overall (Topic 815-10), and Fair Value Measurement – Overall (Topic 820-10). The majority of the amendments in ASU 2018-09 will be effective in annual periods beginning after December 15, 2018. The Company is currently evaluating and assessing the impact this guidance will have on its unaudited condensed consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”). The amendments in ASU 2018-10 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) and have the same effective and transition requirements as ASU 2016-02. Upon the effective date, ASU 2018-10 will supersede the current lease guidance in ASC Topic 840, Leases. Under the new guidance, lessees will be required to recognize for all leases, with the exception of short-term leases, a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis. Concurrently, lessees will be required to recognize a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2018-10 is effective for emerging growth companies for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The guidance is required to be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative periods presented in the financial statements. The Company is currently assessing the impact this guidance will have on its unaudited condensed consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements,” (“ASU 2018-11”). The amendments in ASU 2018-11 related to transition relief on comparative reporting at adoption affect all entities with lease contracts that choose the additional transition method and separating components of a contract affect only lessors whose lease contracts qualify for the practical expedient. The amendments in ASU 2018-11 are effective for emerging growth companies for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is currently assessing the impact this guidance will have on its unaudited condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements associated with fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2018 2017 Options 3,588,451 3,275,700 Warrants 3,413,403 3,644,956 Convertible notes 2,986,487 [1] 509,542 Total potentially dilutive shares 9,988,341 7,430,198 [1] As of September 30, 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 24,710,731 shares of common stock reserved for future note conversions.

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: September 30, 2018 December 31, 2017 Accrued payroll and other accrued expenses $ 347,680 $ 350,173 Accrued research and development expenses 626,175 636,175 Accrued general and administrative expenses 930,482 604,308 Accrued director compensation 432,500 282,500 Deferred rent 39,462 50,395 Total accrued expenses 2,376,299 1,923,551 Less: accrued expenses, current portion 2,376,299 1,885,551 Accrued expenses, non-current portion $ - $ 38,000

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the nine months ended September 30, 2018 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2017 $ 845,000 $ 2,029,870 [1] $ 1,124,465 $ (337,485 ) $ 3,661,850 Issuances - 3,800,728 [2] 128,000 - 3,928,728 Exchanges for equity (95,000 ) (1,600,676 ) (542,760 ) 55,673 (2,182,763 ) Conversions to equity - (105,000 ) - - (105,000 ) Repayments (30,000 ) (403,280 ) - 24,973 (408,307 ) Extinguishment of notes payable - (407,295 )[2] - - (407,295 ) Recognition of debt discount - - - (2,456,892 ) (2,456,892 ) Accretion of interest expense - 7,782 177,283 242,843 427,908 Amortization of debt discount - - - 1,884,116 1,884,116 Outstanding, September 30, 2018 $ 720,000 $ 3,322,129 [1][3] $ 886,988 $ (586,772 ) $ 4,342,345 [1] As of September 30, 2018 and December 31, 2017, a portion of convertible notes with an aggregate principal balance of $1,202,693 and $1,777,788, respectively, was currently convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of September 30, 2018 and December 31, 2017, a portion of convertible notes with an aggregate principal balance of $0 and $252,082, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised that conversion right, the respective holder had the right to accelerate the conversion of up to $0 and $196,666 of principal into shares of common stock at September 30, 2018 and December 31, 2017, respectively, at the same conversion price. [2] During the nine months ended September 30, 2018, convertible notes in the aggregate principal amount of $407,295 were issued concurrently with the extinguishment of certain convertible notes payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other for additional details. [3] As of September 30, 2018, outstanding convertible notes in the aggregate principal amount of $80,000 were past maturity. See Note 9 – Subsequent Events for details regarding the exchange of such aggregate principal amount. As of September 30, 2018, a portion of convertible notes with an aggregate principal balance of $2,119,436, which are not currently convertible, will become convertible subsequent to September 30, 2018 into shares of the Company's common stock at the election of the respective holder.

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Share Based Payment Award Stock Warrants Valuation Assumptions	In applying the Black-Scholes option pricing model to warrants granted or issued, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate 2.73% - 2.83 % 1.99% - 2.14 % 1.92% - 2.83 % 1.98% - 2.33 % Contractual term (years) 5.00 5.00 1.98 - 5.00 5.00 Expected volatility 139 % 130 % 128% - 139 % 120% - 132 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the nine months ended September 30, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2017 3,435,134 $ 4.47 Issued 191,521 3.82 Exercised (207,084 ) 2.00 Expired (6,168 ) 44.92 Outstanding, September 30, 2018 3,413,403 $ 4.33 2.1 $ - Exercisable, September 30, 2018 3,413,403 $ 4.33 2.1 $ -
Schedule of Stock Warrant Activity	The following table presents information related to stock warrants at September 30, 2018: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $3.50 - $3.99 70,000 4.8 70,000 $4.00 - $4.99 3,024,079 2.0 3,024,079 $5.00 - $5.99 195,989 2.7 195,989 $6.00 - $7.99 40,000 1.8 40,000 $8.00 - $9.99 2,500 1.2 2,500 $10.00 - $14.99 40,400 1.5 40,400 $15.00 - $19.99 35,435 0.9 35,435 $20.00 - $40.00 5,000 0.2 5,000 3,413,403 2.1 3,413,403
Schedule of Share Based Payment Award Stock Option Granted Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate 2.74 % 1.78% - 1.88 % 2.44% - 2.74 % 1.77% - 1.88 % Expected term (years) 5.01 6.00 5.00 - 9.69 5.50 - 6.00 Expected volatility 139 % 130 % 129% - 139 % 120% - 130 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Stock Option Activity	A summary of the option activity during the nine months ended September 30, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2017 3,122,202 $ 4.25 Granted 535,000 3.32 Forfeited (68,751 ) 4.01 Outstanding, September 30, 2018 3,588,451 $ 4.12 7.5 $ 1,250 Exercisable, September 30, 2018 2,590,627 $ 4.43 6.9 $ 625
Schedule of Stock Option by Exercise Price	The following table presents information related to stock options at September 30, 2018: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $1.70 - $2.99 218,500 8.2 77,003 $3.00 - $3.99 2,127,000 8.1 1,278,673 $4.00 - $4.99 1,165,451 5.7 1,157,451 $5.00 - $5.99 5,000 5.7 5,000 $6.00 - $19.99 37,500 5.3 37,500 $20.00 - $30.00 35,000 3.5 35,000 3,588,451 6.9 2,590,627
Schedule of Stock Option Expense	The following table presents information related to stock option expense: Weighted Average For the For the Remaining Three Months Ended Nine Months Ended Unrecognized at Amortization September 30, September 30, September 30, Period 2018 2017 2018 2017 2018 (Years) Consulting $ 163,757 $ 301,622 $ 669,574 $ 1,284,781 $ 400,486 0.7 Research and development 98,148 157,960 242,586 522,883 289,070 1.5 General and administrative (488,463 ) 281,785 523,089 1,145,611 1,812,016 0.4 $ (226,558 ) $ 741,367 $ 1,435,249 $ 2,953,275 $ 2,501,572 0.6

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Changes in Fair Value of Level 3 Derivative Liabilities	The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Beginning balance as of January 1, 2018 $ 216,073 Issuance of derivative liabilities 2,309,536 Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges (2,027,739 ) Change in fair value of derivative liabilities 557,274 Reclassification of derivative liabilities to equity (105,187 ) Ending balance as of September 30, 2018 $ 949,957
Summary of Derivative Liabilities Fair Value Assumption	In applying the Multinomial Lattice and Black-Scholes option pricing models to derivatives issued and outstanding during the nine months ended September 30, 2018, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate 1.93% - 2.94 % 1.30% - 1.34 % 1.22% - 2.94 % 1.30% - 1.34 % Expected term (years) 0.25 - 5.00 0.75 - 0.91 0.25 - 5.00 0.75 - 0.91 Expected volatility 120% - 208 % 111% - 133 % 100% - 208 % 111% - 133 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %

Going Concern and Management'_2

Going Concern and Management's Plans (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Working capital deficiency	$ 8,741,382		$ 8,741,382
Stockholder's deficiency	(8,938,147)		(8,938,147)		$ (6,836,568)
Net loss	(2,925,261)	$ (2,052,088)	(8,947,344)	$ (7,585,025)
Exchanges for equity			2,182,763
Subsequent to September 30, 2018 [Member]
Proceeds from debt financings			1,138,980
Exchanges for equity			1,303,023
Repayments of debt			191,391
Note payable past due	$ 7,500		$ 7,500

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Royalty revenue	$ 26,000	$ 16,000	$ 82,000	$ 43,000
Sublicense Agreement [Member]
Royalty revenue	$ 26,000	$ 16,000	$ 82,000	$ 43,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares	9 Months Ended
	Sep. 30, 2018		Sep. 30, 2017
Total potentially dilutive shares	9,988,341		7,430,198
Options [Member]
Total potentially dilutive shares	3,588,451		3,275,700
Warrants [Member]
Total potentially dilutive shares	3,413,403		3,644,956
Convertible Notes [Member]
Total potentially dilutive shares	2,986,487	[1]	509,542
[1]	As of September 30, 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 24,710,731 shares of common stock reserved for future note conversions.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) (Parenthetical)	Sep. 30, 2018shares
Accounting Policies [Abstract]
Common stock, reserved for future issuance	24,710,731

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued Expenses and Other Current Liabilities [Line Items]
Less: accrued expenses, current portion	$ 2,376,299	$ 1,885,551
Accrued expenses, non-current portion		38,000
Accrued Expenses and Other Current Liabilities [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Accrued payroll and other accrued expenses	347,680	350,173
Accrued research and development expenses	626,175	636,175
Accrued general and administrative expenses	930,482	604,308
Accrued director compensation	432,500	282,500
Deferred rent	39,462	50,395
Total accrued expenses	2,376,299	1,923,551
Less: accrued expenses, current portion	2,376,299	1,885,551
Accrued expenses, non-current portion		$ 38,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Debt Instrument [Line Items]
Repaid a certain related party note in the principal amount			$ 38,500	$ 50,515
Debt instrument principal conversion values			110,636
Loss on extinguishment of notes payable	$ (320,383)		(384,171)	(59,938)
Note payable in principal amount	$ 0		0		$ 252,082
Proceeds from issuance of notes payable			$ 3,062,217	1,385,000
Debt instrument, convertible, conversion price	$ 0.10		$ 0.10
Extinguishments of bifurcated embedded conversion options			$ 1,767,362
Aggregate value of shares issued			100,000
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 0		$ 196,666
Lenders [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion share			1,707,181
Accrued interest	$ 91,601		$ 91,601
Lenders [Member] | Minimum [Member]
Debt Instrument [Line Items]
Stock issued price per share	$ 0.59		$ 0.59
Lenders [Member] | Maximum [Member]
Debt Instrument [Line Items]
Stock issued price per share	1.01		$ 1.01
Related Party Notes [Member]
Debt Instrument [Line Items]
Repaid a certain related party note in the principal amount			$ 30,000
Debt instrument principal conversion values			$ 95,000
Debt instrument principal conversion share			76,000
Stock issued price per share	$ 1.25		$ 1.25
Number of common stock aggregate exchange value			$ 114,000
Loss on extinguishment of notes payable			19,000
Note payable in principal amount	$ 140,000		$ 140,000
Repayments of debt extended due date			Maturity dates ranging between August 2016 to February 2018 to new maturity dates ranging from July 2018 to December 2018
Convertible Notes [Member]
Debt Instrument [Line Items]
Note payable in principal amount	407,295		$ 407,295
Convertible Notes [Member] | Lenders and Consultant [Member]
Debt Instrument [Line Items]
Note payable in principal amount	$ 3,393,433		3,393,433
Variance of convertible note principal and cash proceeds			441,220
Proceeds from issuance of notes payable			2,952,213
Amortized debt discount			309,285
Consulting expense			$ 131,935
Debt conversion, description			The difference of $441,220 was recorded as follows: (i) $309,285 was recorded as a debt discount and will be amortized over the terms of the respective notes and (ii) $131,935 was immediately recognized as consulting expense in the condensed consolidated financial statements.
Debt maturity term			Maturity dates ranging between June 2018 through September 2019.
Convertible Notes [Member] | Lenders and Consultant [Member] | Minimum [Member]
Debt Instrument [Line Items]
Convertible notes bear interest rate	6.00%		6.00%
Convertible Notes [Member] | Lenders and Consultant [Member] | Maximum [Member]
Debt Instrument [Line Items]
Convertible notes bear interest rate	12.00%		12.00%
Convertible Notes [Member] | Noteholder [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 55,000
Note payable in principal amount	$ 3,800,728		$ 3,800,728
Debt conversion, description			(i) $1,351,293 of aggregate principal and the respective interest is convertible into shares of the Company's common stock at the election of the respective holder at any time immediately on or after the issue dates until the respective balances have been paid in full, (ii) $2,262,500 of aggregate principal and the respective interest is convertible into shares of the Company's common stock at the election of the respective holder after the 180th day following the respective issue date until the balance has been paid in full, (iii) $55,000 of principal and respective interest is convertible into shares of the Company's stock at the election of the Company during the five days prior to maturity and ending on the day immediately prior to maturity; however, should the Company elect to convert any portion of the $55,000 of note principal and respective accrued interest, the holder would have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price, and (iv) $170,000 ($131,935 earned as of September 30, 2018) of aggregate principal and the respective interest is convertible from time to time following the respective issue date at the holder's election.
Earned payable	$ 131,935		$ 131,935
Convertible Notes [Member] | Lenders [Member]
Debt Instrument [Line Items]
Number of common stock issued			28,333
Fair value of common stock			$ 42,827
Convertible Notes One [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 675,000
Debt instrument, convertible, conversion price	$ 2		$ 2
Debt conversion fair value percentage			58.00%
Convertible Notes Two [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 978,228
Convertible Notes Two [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	0.75		$ 0.75
Debt conversion fair value percentage			50.00%
Convertible Notes Two [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	1		$ 1
Debt conversion fair value percentage			65.00%
Convertible Notes Three [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 350,000
Debt instrument, convertible, conversion price	$ 2.15		$ 2.15
Convertible Notes Four [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 1,797,500
Debt conversion fair value percentage			58.00%
MPO [Member]
Debt Instrument [Line Items]
Aggregate principal on mandatory prepayment	$ 137,500		$ 137,500
Debt instrument, convertible, conversion percentage			35.00%
Description on debt instrument			Convertible notes issued with MPOs permit the respective holder to demand prepayment of the note, in cash, at a premium of 35% of the then outstanding principal balance and accrued interest during the period between 150 days to 179 days following the respective issuance date.
Convertible Notes Five [Member]
Debt Instrument [Line Items]
Repaid a certain related party note in the principal amount			$ 2,811,500
Description on debt instrument			In the event that the Company prepays a certain note after the 180th day period following the issue date and prior to maturity, the holder is entitled to receive a prepayment premium of 50% on the then outstanding principal balance including accrued interest.
Percentage on prepayment premium	50.00%		50.00%
Convertible Notes Five [Member] | First Ninety Day [Member]
Debt Instrument [Line Items]
Percentage on prepayment premium	30.00%		30.00%
Convertible Notes Five [Member] | Second Ninety Day [Member]
Debt Instrument [Line Items]
Percentage on prepayment premium	40.00%		40.00%
MFN [Member]
Debt Instrument [Line Items]
Note payable in principal amount	$ 1,756,500		$ 1,756,500
MFN [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion percentage			58.00%
MFN [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion percentage			65.00%
Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values			$ 105,000
Debt instrument principal conversion share			97,424
Accrued interest	5,637		$ 5,637
Extinguishments of debt discounts			55,673
Extinguishments of bifurcated embedded conversion options			1,826,304
Conversions, Exchanges and Other [Member] | Embedded Conversion Options [Member]
Debt Instrument [Line Items]
Loss on extinguishment of notes payable			260,377
Amortized debt discount			1,938,759
Extinguishments of bifurcated embedded conversion options			2,199,136
Debt beneficial conversion feature			69,394	$ 10,596
Conversions, Exchanges and Other [Member] | Lender [Member]
Debt Instrument [Line Items]
Loss on extinguishment of notes payable			77,132
Note payable in principal amount	1,600,676		1,600,676
Fair value of common stock			$ 3,548,942
Number of shares issued to lender			1,579,032
Accrued interest	100,503		$ 100,503
Conversions, Exchanges and Other [Member] | Lenders [Member]
Debt Instrument [Line Items]
Note payable in principal amount	681,445		681,445
Amortized debt discount			$ 9,000
Debt maturity term			Maturity dates ranging between December 2017 to July 2018 to new maturity dates ranging from April 2018 to September 2018.
Number of common stock issued			4,500
Fair value of common stock			$ 9,000
Convertible notes payable past due	$ 80,000		80,000
Aggregate value of shares issued			$ 407,295
Conversions, Exchanges and Other [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 0.82		$ 0.82
Conversions, Exchanges and Other [Member] | Minimum [Member] | Lender [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	0.83		0.83
Conversions, Exchanges and Other [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	2.02		2.02
Conversions, Exchanges and Other [Member] | Maximum [Member] | Lender [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 2.38		$ 2.38
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Loss on extinguishment of notes payable			$ 106,682
Note payable in principal amount	$ 403,280		403,280
Aggregate principal on prepayment premiums	81,709		81,709
Accrued interest	21,625		21,625
Extinguishments of debt discounts			24,973
Derivative liability	$ 2,199,136		$ 2,199,136
Three Convertible Promissory Notes [Member] | Lenders [Member]
Debt Instrument [Line Items]
Stock issued price per share	$ 0.10		$ 0.10
Note payable in principal amount	$ 407,295		$ 407,295
Debt conversion, description			The conversion terms of the acquired notes were modified such that the new notes are convertible, at the option of holder, into shares of common stock of the Company at a conversion price equal to the greater of (a) 65% (previously 80%) of fair value of the Company's common stock or (b) $0.10 per share (previously $1.00 per share).
Convertible notes bear interest rate	8.00%		8.00%
Fair value of common stock			$ 260,377
Percentage on prepayment premium	65.00%		65.00%
Accrued interest	$ 7,782		$ 7,782
Debt instrument maturity date			Aug. 30, 2019
New Convertible Notes [Member] | Lenders [Member]
Debt Instrument [Line Items]
Loss on extinguishment of notes payable			$ 58,942
Note payable in principal amount	608,730		608,730
Derivative liability	201,435		201,435
Aggregate value of shares issued			407,295
Convertible debt fair value	260,377		260,377
Other Notes [Member]
Debt Instrument [Line Items]
Note payable in principal amount	128,000		128,000
Proceeds from issuance of notes payable			110,000
Amortized debt discount			18,000
Fair value of common stock			$ 9,627
Number of shares issued to lender			6,500
Other Notes [Member] | Lender [Member]
Debt Instrument [Line Items]
Loss on extinguishment of notes payable			$ 122,415
Note payable in principal amount	542,760		$ 542,760
Number of common stock issued			451,493
Accrued interest	$ 12,064		$ 12,064
Aggregate value of shares issued			$ 677,239
Other Notes [Member] | Minimum [Member] | Lender [Member]
Debt Instrument [Line Items]
Stock issued price per share	$ 1		$ 1
Other Notes [Member] | Maximum [Member] | Lender [Member]
Debt Instrument [Line Items]
Stock issued price per share	$ 1.50		$ 1.50
Other Notes [Member] | Lender [Member]
Debt Instrument [Line Items]
Note payable in principal amount	$ 1,309,747		$ 1,309,747
Amortized debt discount			$ 60,000
Debt maturity term			Maturity dates ranging between December 2017 to October 2018 to new maturity dates ranging from March 2018 to January 2019.
Number of shares issued to lender			35,000
Other Notes [Member] | Minimum [Member] | Lender [Member]
Debt Instrument [Line Items]
Convertible notes bear interest rate	0.00%		0.00%
Other Notes [Member] | Maximum [Member] | Lender [Member]
Debt Instrument [Line Items]
Convertible notes bear interest rate	8.00%		8.00%

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Outstanding beginning				$ 3,661,850
Issuances				3,928,728
Exchanges to equity				(2,182,763)
Conversion to equity				(105,000)
Repayments				(433,280)	$ (114,000)
Extinguishment of notes payable				(407,295)
Recognition of debt discount				(2,456,892)
Accretion of interest expense				427,908	133,431
Amortization of debt discount		$ 540,488	$ 159,977	1,884,116	$ 376,886
Outstanding ending		4,342,345		4,342,345
Convertible Notes Payable [Member]
Outstanding beginning	[1]			2,029,870
Issuances	[2]			3,800,728
Exchanges to equity				(1,600,676)
Conversion to equity				(105,000)
Repayments				(403,280)
Extinguishment of notes payable				(407,295)
Recognition of debt discount
Accretion of interest expense				7,782
Amortization of debt discount
Outstanding ending	[1],[3]	3,322,129		3,322,129
Other Notes [Member]
Outstanding beginning				1,124,465
Issuances				128,000
Exchanges to equity				(542,760)
Conversion to equity
Repayments
Extinguishment of notes payable
Recognition of debt discount
Accretion of interest expense				177,283
Amortization of debt discount
Outstanding ending		886,988		886,988
Debt Discount [Member]
Outstanding beginning				(337,485)
Issuances
Exchanges to equity				55,673
Conversion to equity
Repayments				24,973
Extinguishment of notes payable
Recognition of debt discount				(2,456,892)
Accretion of interest expense				242,843
Amortization of debt discount				1,884,116
Outstanding ending		(586,772)		(586,772)
Related Party Notes [Member]
Outstanding beginning				845,000
Issuances
Exchanges to equity				(95,000)
Conversion to equity
Repayments				(30,000)
Extinguishment of notes payable
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Outstanding ending		$ 720,000		$ 720,000
[1]	As of September 30, 2018 and December 31, 2017, a portion of convertible notes with an aggregate principal balance of $1,202,693 and $1,777,788, respectively, was currently convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of September 30, 2018 and December 31, 2017, a portion of convertible notes with an aggregate principal balance of $0 and $252,082, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised that conversion right, the respective holder had the right to accelerate the conversion of up to $0 and $196,666 of principal into shares of common stock at September 30, 2018 and December 31, 2017, respectively, at the same conversion price.
[2]	During the nine months ended September 30, 2018, convertible notes in the aggregate principal amount of $407,295 were issued concurrently with the extinguishment of certain convertible notes payable in the same aggregate principal amount. See below within Note 5 - Notes Payable - Conversions, Exchanges and Other for additional details.
[3]	As of September 30, 2018, outstanding convertible notes in the aggregate principal amount of $80,000 were past maturity. See Note 9 - Subsequent Events for details regarding the exchange of such aggregate principal amount. As of September 30, 2018, a portion of convertible notes with an aggregate principal balance of $2,119,436, which are not currently convertible, will become convertible subsequent to September 30, 2018 into shares of the Company's common stock at the election of the respective holder.

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Debt instrument, face amount	$ 0	$ 252,082
Debt conversion, converted instrument, amount	110,636
Maximum [Member]
Debt conversion, converted instrument, amount	0	196,666
Convertible Notes Payable [Member]
Debt instrument, face amount	1,202,693	$ 1,777,788
Convertible Notes [Member]
Debt instrument, face amount	407,295
Convertible Notes [Member] | Subsequent to September 30, 2018 [Member]
Convertible notes with a principal balance	2,119,436
Convertible Notes [Member] | Past Maturity [Member]
Debt instrument, face amount	$ 80,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jul. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jul. 10, 2018	Dec. 31, 2017
Debt instrument face amount		$ 0		$ 0			$ 252,082
Debt instrument, convertible, conversion price		$ 0.10		$ 0.10
Exercise price of options		$ 4.12		$ 4.12			$ 4.25
Number of options granted during period				535,000
Rent expense		$ 31,000	$ 32,000	$ 92,000	$ 96,000
Scientific Advisory Services Agreement [Member]
Options to purchase common stock	25,000
Option expiration term	5 years
Exercise price of options	$ 1.70
Number of options vested during period	12,500
Number of options expected to be vested	12,500
Option excercisable period	1 year
Number of options granted during period	5,000
Convertible Notes [Member]
Debt instrument face amount		$ 407,295		$ 407,295
Business Advisory Services [Member] | Extension 1 [Member]
Warrant term				5 years
Advisory services expired date				Dec. 31, 2018
Warrants to purchase common stock		30,000		30,000
Exercise price per share		$ 4		$ 4
Fair value of aggregate of warrant				$ 48,192
Accrued consulting fees		$ 38,000		$ 38,000
Number of shares of common stock issued in exchange of accrued expenses				19,000
Business Advisory Services [Member] | Extension 2 [Member]
Warrant term				2 years
Warrants to purchase common stock		4,750		4,750
Exercise price per share		$ 4		$ 4
Consulting Agreement [Member] | Consultant [Member]
Warrant term	5 years
Warrants to purchase common stock	35,000
Exercise price per share	$ 4
Debt maturity, description	Previously expired consulting agreement from May 2018 to December 2018.			The notes mature at dates between January 2019 and February 2019
Convertible notes bear interest rate		10.00%		10.00%
Debt instrument, convertible, conversion price		$ 0.10		$ 0.10
Debt conversion fair value percentage				65.00%
Debt instrument prepayment premium		25.00%		25.00%
Warrant purchase for common stock, value	$ 43,106
Consulting Agreement [Member] | Consultant [Member] | Maximum [Member]
Debt instrument, convertible, conversion price		$ 1.75		$ 1.75
Consulting Agreement [Member] | Consultant [Member] | Convertible Notes [Member]
Debt instrument face amount						$ 170,000
Consulting Agreement [Member] | Consultant [Member] | Notes Payable [Member]
Debt instrument face amount		$ 131,935		$ 131,935
Employment Agreements [Member]
Accrued bonuses		68,000		68,000			$ 87,000
Employment Agreements [Member] | December 31, 2018 [Member] | Certain Officers [Member]
Accrued bonuses		178,000		$ 178,000
Employment Agreements [Member] | Chief Executive Officer [Member]
Employment agreements, description				In March 2018, the Company and its CEO agreed to an extension of the expiration date of his employment agreement from June 30, 2018 to December 31, 2019. In connection with the extension, the CEO is entitled to new performance-based cash bonuses payable for the years ending December 31, 2018 and 2019, such that an aggregate of up to 50% of the CEO's then annual base salary per annum could be earned for such year pursuant to the satisfaction of such goals.
Employment Agreements [Member] | Chief Executive Officer [Member] | December 31, 2018 [Member]
Accrued bonuses		$ 400,938		$ 400,938

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Number of common stock issued for services, value				$ 38,000
Stock based compensation expenses				1,579,046	$ 3,084,753
Warrant modification charge				$ 3,100
Exercise prices of stock options				$ 3.32
Consultant [Member]
Number of common stock issued for services		35,000	10,000	35,000	10,000
Number of common stock issued for services, value		$ 52,500	$ 20,000	$ 52,500	$ 20,000
Warrant And Option Valuation [Member] | Minimum [Member]
Estimated forfeitures related to option grants at an annual rate				0.00%
Warrant And Option Valuation [Member] | Maximum [Member]
Estimated forfeitures related to option grants at an annual rate					5.00%
Common Stock and Warrant Offering [Member]
Number of common stock shares issued				70,000
Warrant term				5 years
Warrants to purchase common stock		70,000		70,000
Exercise price per share		$ 3.50		$ 3.50
Fair value adjustment of warrants				$ 87,300
Derivative liabilities		$ 75,000		75,000
Common Stock and Warrant Offering [Member] | Investor [Member]
Aggregate gross proceeds of warrants				175,000
Stock Warrants [Member] | Consultant [Member]
Stock based compensation expenses		$ 43,105	$ 40,275	$ 91,297	$ 111,478
Warrant Modifications and Exercises [Member]
Exercise price per share		$ 2		$ 2
Aggregate gross proceeds of warrants				$ 414,168
Stock issued pursuant to warrant exercises				207,084
Warrant Modifications and Exercises [Member] | Additional Two-Year Warrants [Member]
Warrant term				2 years
Exercise price per share		$ 4		$ 4
Number of warrants issued				51,771
Warrant Modifications and Exercises [Member] | Investor [Member]
Warrants to purchase common stock		10,000		10,000
Warrant expiration term				The expiration date of the warrant was extended from an expiration date in May 2021 to a new expiration date in May 2023.
Warrant modification charge				$ 3,100
Warrant Modifications and Exercises [Member] | Minimum [Member]
Exercise price per share		$ 4		$ 4
Warrant Modifications and Exercises [Member] | Minimum [Member] | Investor [Member]
Exercise price per share		4		4
Warrant Modifications and Exercises [Member] | Maximum [Member]
Exercise price per share		5		5
Warrant Modifications and Exercises [Member] | Maximum [Member] | Investor [Member]
Exercise price per share		5		5
Warrants [Member]
Weighted average estimated fair value of warrants granted per share		1.24	$ 1.54	1.23	$ 1.60
Stock Option [Member]
Weighted average estimated fair value of options granted per share		$ 2.92	$ 2.54	$ 1.42	$ 2.75
Stock Option [Member] | Consultant [Member]
Exercise prices of stock options	$ 3.20
Stock option term	10 years
Number of option to purchase shares	10,000
Shares vested term	3 years
Stock option grant date fair value	$ 33,700
Stock Option [Member] | Senior VP [Member]
Exercise prices of stock options	$ 3.40
Number of option to purchase shares	500,000
Stock option grant date fair value	$ 1,491,300

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Share Based Payment Award Stock Warrants Valuation Assumptions (Details) - Warrant [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Contractual term (years)	5 years	5 years		5 years
Expected volatility	139.00%	130.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Risk free interest rate	2.73%	1.99%	1.92%	1.98%
Contractual term (years)			1 year 11 months 23 days
Expected volatility			128.00%	120.00%
Maximum [Member]
Risk free interest rate	2.83%	2.14%	2.83%	2.33%
Contractual term (years)			5 years
Expected volatility			136.00%	132.00%

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Number of Warrants Exercisable, Balance | shares	2,590,627
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 4.25
Weighted Average Exercise Price Outstanding, Issued	3.32
Weighted Average Exercise Price Outstanding, Expired	4.01
Weighted Average Exercise Price Outstanding, Ending Balance	4.12
Weighted Average Exercise Price Exercisable, Balance	$ 4.43
Weighted Average Remaining Life In Years Outstanding	7 years 6 months
Weighted Average Remaining Life In Years Exercisable	6 years 10 months 25 days
Aggregate Intrinsic Value, Outstanding | $	$ 1,250
Aggregate Intrinsic Value, Exercisable | $	$ 625
Warrant [Member]
Number of Warrants Outstanding, Beginning Balance | shares	3,435,134
Number of Warrants Outstanding, Issued | shares	191,521
Number of Warrants Outstanding, Exercised | shares	(207,084)
Number of Warrants Outstanding, Expired | shares	(6,168)
Number of Warrants Outstanding, Ending Balance | shares	3,413,403
Number of Warrants Exercisable, Balance | shares	3,413,403
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 4.47
Weighted Average Exercise Price Outstanding, Issued	3.82
Weighted Average Exercise Price Outstanding, Exercised	2
Weighted Average Exercise Price Outstanding, Expired	44.92
Weighted Average Exercise Price Outstanding, Ending Balance	4.33
Weighted Average Exercise Price Exercisable, Balance	$ 4.33
Weighted Average Remaining Life In Years Outstanding	2 years 1 month 6 days
Weighted Average Remaining Life In Years Exercisable	2 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Stock Warrant (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,413,403
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	3,413,403
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	70,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	70,000
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,024,079
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years
Warrants Exercisable, Exercisable Number of Warrants	3,024,079
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	195,989
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	195,989
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	2,500
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,400
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 6 months
Warrants Exercisable, Exercisable Number of Warrants	40,400
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	35,435
Warrants Exercisable, Weighted Average Remaining Life In Years	10 months 25 days
Warrants Exercisable, Exercisable Number of Warrants	35,435
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	5,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	5,000
Minimum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.50
Minimum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	4
Minimum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5
Minimum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	6
Minimum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	8
Minimum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	10
Minimum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	15
Minimum [Member] | Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	20
Maximum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	3.99
Maximum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	4.99
Maximum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5.99
Maximum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	7.99
Maximum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	9.99
Maximum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	14.99
Maximum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	19.99
Maximum [Member] | Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 40

Stockholders' Deficiency - Sc_3

Stockholders' Deficiency - Schedule of Share Based Payment Award Stock Option Granted Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock Option [Member]
Risk free interest rate	2.74%
Expected term (years)	5 years 4 days	6 years
Expected volatility	139.00%	130.00%
Expected dividends	0.00%	0.00%
Stock Options [Member]
Expected dividends			0.00%	0.00%
Minimum [Member] | Stock Option [Member]
Risk free interest rate		1.78%
Minimum [Member] | Stock Options [Member]
Risk free interest rate			2.44%	1.77%
Expected term (years)			5 years	5 years 6 months
Expected volatility			129.00%	120.00%
Maximum [Member] | Stock Option [Member]
Risk free interest rate		1.88%
Maximum [Member] | Stock Options [Member]
Risk free interest rate			2.74%	1.88%
Expected term (years)			9 years 8 months 9 days	6 years
Expected volatility			139.00%	130.00%

Stockholders' Deficiency - Sc_4

Stockholders' Deficiency - Schedule of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Equity [Abstract]
Number of Options, Outstanding, beginning | shares	3,122,202
Number of Options, Granted | shares	535,000
Number of Options, Forfeited | shares	(68,751)
Number of Options, Outstanding, ending | shares	3,588,451
Number of Options, Exercisable | shares	2,590,627
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 4.25
Weighted Average Exercise Price, Granted | $ / shares	3.32
Weighted Average Exercise Price, Forfeited | $ / shares	4.01
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	4.12
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 4.43
Weighted Average Remaining Life In Years Outstanding	7 years 6 months
Weighted Average Remaining Life In Years Exercisable	6 years 10 months 25 days
Aggregate Intrinsic Value, Outstanding | $	$ 1,250
Aggregate Intrinsic Value, Exercisable | $	$ 625

Stockholders' Deficiency - Sc_5

Stockholders' Deficiency - Schedule of Stock Option by Exercise Price (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	3,588,451
Options Exercisable, Weighted Average Remaining Life In Years	6 years 10 months 25 days
Options Exercisable, Exercisable Number of Options	2,590,627
Exercise Price One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	218,500
Options Exercisable, Weighted Average Remaining Life In Years	8 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	77,003
Exercise Price One [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 1.70
Exercise Price One [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 2.99
Exercise Price Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	2,127,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	1,278,673
Exercise Price Two [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3
Exercise Price Two [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	1,165,451
Options Exercisable, Weighted Average Remaining Life In Years	5 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	1,157,451
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	5 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	5,000
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	37,500
Options Exercisable, Weighted Average Remaining Life In Years	5 years 3 months 19 days
Options Exercisable, Exercisable Number of Options	37,500
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	3 years 6 months
Options Exercisable, Exercisable Number of Options	35,000
Exercise Price Six [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 20
Exercise Price Six [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 30

Stockholders' Deficiency - Sc_6

Stockholders' Deficiency - Schedule of Stock Option Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Options [Member]
Unrecognized expense	$ 2,501,572		$ 2,501,572
Option [Member]
Stock-based compensation expense	(226,558)	$ 741,367	$ 1,435,249	$ 2,953,275
Weighted Average Remaining Amortization Period			7 months 6 days
Consulting Expenses [Member] | Options [Member]
Stock-based compensation expense	163,757	301,622
Unrecognized expense	400,486		$ 400,486
Research and Development Expense [Member] | Options [Member]
Stock-based compensation expense	98,148	157,960	242,586	522,883
Unrecognized expense	289,070		$ 289,070
Weighted Average Remaining Amortization Period			1 year 6 months
General and Administrative Expense [Member] | Options [Member]
Stock-based compensation expense	(488,463)	$ 281,785	$ 523,089	1,145,611
Unrecognized expense	$ 1,812,016		$ 1,812,016
Weighted Average Remaining Amortization Period			4 months 24 days
Consulting [Member] | Options [Member]
Stock-based compensation expense			$ 669,574
Weighted Average Remaining Amortization Period			8 months 12 days
Consulting Expense [Member] | Options [Member]
Stock-based compensation expense				$ 1,284,781

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges		$ 2,027,739
Reclassification of derivative liabilities to equity		105,187	$ 4,780
Gain on derivative liabilities		557,274
Consultant [Member]
Fair value of derivative liabilities	$ 37,119	37,119
Gain on derivative liabilities		1,719	$ 1,719
Warrants [Member]
Fair value of derivative liabilities	152,017	152,017
Gain on derivative liabilities	33,831	2,997
Embedded Conversion Options [Member]
Fair value of derivative liabilities	760,821	760,821
Gain on derivative liabilities	579,772	558,552
Warrant [Member]
Derivative liabilities	75,000	75,000
Stock Options [Member]
Derivative liabilities	35,400	35,400
Convertible Notes Payable [Member]
Derivative liabilities	$ 2,199,136	$ 2,199,136

Derivative Liabilities - Summar

Derivative Liabilities - Summary of Changes in Fair Value of Level 3 Derivative Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities, beginning balance	$ 216,073
Issuance of derivative liabilities	2,309,536
Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges	(2,027,739)
Change in fair value of derivative liabilities	557,274
Reclassification of derivative liabilities to equity	(105,187)	$ (4,780)
Derivative liabilities, ending balance	$ 949,957

Derivative Liabilities - Summ_2

Derivative Liabilities - Summary of Derivative Liabilities Fair Value Assumption (Details) - Valuation Technique, Option Pricing Model [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Risk Free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentages	1.93%	1.30%	1.22%	1.30%
Risk Free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentages	2.94%	1.34%	2.94%	1.34%
Expected Term [Member] | Minimum [Member]
Fair value assumptions, measurement input, term	2 months 30 days	9 months	2 months 30 days	9 months
Expected Term [Member] | Maximum [Member]
Fair value assumptions, measurement input, term	5 years	10 months 28 days	5 years	10 months 28 days
Expected Volatility [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentages	120.00%	111.00%	100.00%	111.00%
Expected Volatility [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentages	208.00%	133.00%	208.00%	133.00%
Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0.00%	0.00%	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jul. 31, 2018	Oct. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Number of options granted during period			535,000
Exercise price of options			$ 4.12		$ 4.25
Debt instrument conversion price			$ 0.10
Debt instrument face amount			$ 0		$ 252,082
Repayments of convertible notes payable			433,280	$ 114,000
Convertible Promissory Notes [Member]
Aggregate principal amount of convertible notes payable			$ 1,230,000
Convertible notes bear interest rate			12.00%
Proceeds from issuance of convertible notes			$ 1,138,980
Debt maturity term			Maturity with original maturity dates ranging between April 2019 to October 2019.
Debt instrument face amount			$ 55,000
Description on debt instrument			Outstanding principal and balance and accrued interest during the period between 150 days to 179 days following the respective issuance date.
Accrued interest			$ 6,749
Repayments of convertible notes payable			135,022
Aggregate principal on prepayment premiums			49,620
Convertible Promissory Notes One [Member]
Aggregate principal amount of convertible notes payable			$ 880,000
Debt instrument conversion rate			58.00%
Convertible Promissory Notes Two [Member]
Aggregate principal amount of convertible notes payable			$ 350,000
Debt instrument conversion rate			58.00%
Employees, Directors and Scientific Advisory Board Members [Member]
Option expiration term			10 years
Number of options granted during period			995,000
Exercise price of options			$ 1.23
Number of options vested during period			216,667
One Year Anniversary [Member] | Employees, Directors and Scientific Advisory Board Members [Member]
Number of options expected to be vested			331,671
Two Year Anniversary [Member] | Employees, Directors and Scientific Advisory Board Members [Member]
Number of options expected to be vested			331,666
Three Year Anniversary [Member] | Employees, Directors and Scientific Advisory Board Members [Member]
Number of options expected to be vested			114,996
Warrant [Member]
Exercise price of options			$ 4.33		$ 4.47
Consultant [Member] | Convertible Promissory Notes [Member]
Aggregate principal amount of convertible notes payable			$ 90,000
Debt maturity date			Apr. 30, 2019
Convertible notes bear interest rate			10.00%
Debt instrument conversion price			$ 1.27
Debt conversion fair value percentage			65.00%
Percentage on prepayment premium			25.00%
Consultant [Member] | Warrant [Member]
Warrant term			5 years
Warrants to purchase common stock			75,000
Exercise price per share			$ 2
Lenders [Member]
Aggragate principal amount			$ 1,211,422
Accrued interest			$ 91,601
Debt instrument principal conversion share			1,707,181
Lenders [Member] | Minimum [Member]
Shares issued price per share			$ 0.59
Lenders [Member] | Maximum [Member]
Shares issued price per share			$ 1.01
Lenders [Member] | Convertible Promissory Notes [Member]
Aggregate principal amount of convertible notes payable			$ 635,000
Common stock issued in connection with debt issuance			24,916
Lenders [Member] | First Ninety Day [Member] | Convertible Promissory Notes [Member]
Percentage on prepayment premium			35.00%
Lenders [Member] | Second Ninety Day [Member] | Convertible Promissory Notes [Member]
Percentage on prepayment premium			40.00%
Scientific Advisory Services Agreement [Member]
Option expiration term	5 years
Number of options granted during period	5,000
Exercise price of options	$ 1.70
Number of options vested during period	12,500
Number of options expected to be vested	12,500
Subsequent Event [Member] | Employment Agreements [Member] | Former Senior VP [Member]
Number of unvested option to purchase		500,000
Subsequent Event [Member] | Employment Agreements [Member] | Executive Vice President [Member]
Option expiration term		10 years
Number of options granted during period		500,000
Exercise price of options		$ 1.42
Subsequent Event [Member] | Employment Agreements [Member] | Executive Vice President [Member] | Vested Immediately [Member]
Number of options vested during period		100,000
Subsequent Event [Member] | Employment Agreements [Member] | Executive Vice President [Member] | Vested Earlier [Member]
Number of options vested during period		150,000
Subsequent Event [Member] | Employment Agreements [Member] | Executive Vice President [Member] | Second Anniversary [Member]
Number of options expected to be vested		250,000
Subsequent Event [Member] | Scientific Advisory Services Agreement [Member] | Disc Committee Chairman [Member]
Option expiration term		10 years
Number of options granted during period		75,000
Exercise price of options		$ 1.80
Number of options vested during period		25,000
Number of options expected to be vested		50,000